Regions – Page 23 – pharmaceutical daily

April 11, 2022 Off

Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial

By Author

Bristol Myers Squibb (NYSE: BMY) has announced results from the Phase 3 CheckMate -816 trial, which showed that neoadjuvant treatment with three cycles of Opdivo (nivolumab) in combination with chemotherapy significantly improved event-free survival (EFS), a primary endpoint, compared to chemotherapy alone in patients with resectable non-small cell lung cancer (NSCLC).

April 11, 2022 Off

Recipharm completes US biologics acquisitions

By Author

Recipharm, a global contract development and manufacturing organisation (CDMO), has announces the closing of its acquisitions of advanced therapy CDMO Arranta Bio and virotherapy CDMO Vibalogics.

April 11, 2022 Off

Jorge Gomez Joins Moderna as Chief Financial Officer

By Author

Moderna, Inc., (Nasdaq:MRNA) has announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna’s Executive Committee and report to Chief Executive Officer, Stéphane Bancel.

April 11, 2022 Off

Tjoapack doubles packaging capacity with completed Netherlands facility expansion

By Author

Global pharmaceutical contract packaging organisation (CPO), Tjoapack has completed its expansion plans following a €10m+ plus investment at its Etten-Leur facility in the Netherlands.

April 11, 2022 Off

Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates

By Author

Moderna, Inc. (NASDAQ:MRNA), has announced the first participants have been dosed in the Phase 1/2 study of the company’s seasonal influenza vaccine candidates, mRNA-1020 and mRNA-1030.

April 11, 2022 Off

Actinium Pharmaceuticals Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR

By Dino Mustafić

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), has announced positive results from preclinical studies evaluating an anti-HER3 antibody, conjugated with an Actinium-225 (Ac-225) radioisotope payload, for targeting HER3-positive non-small cell lung cancer (NSCLC) cells.

April 11, 2022 Off

Adrenomed Gets €7,4M to Develop Covid-19 Drug

By Author

Adrenomed AG, the vascular integrity company, has announced that its proprietary sepsis drug candidate Adrecizumab (HAM8101) received a funding commitment of € 7.4 million from the German Federal Ministry of Education and Research (BMBF) as part of the German funding initiatives for the clinical development of COVID-19 drugs and their manufacturing capabilities.

April 11, 2022 Off

SciRhom Starts CMC Development of its First Drug Candidate for Clinical Development

By Author

SciRhom GmbH has nominated the anti-iRhom2 antibody it will advance into clinical development. For this antibody, the company has closed an agreement with a top-tier biopharmaceutical manufacturer for the CMC development.

April 10, 2022 Off

Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer

By Dino Mustafić

Pfizer Inc. (NYSE: PFE) announced updated results from the Phase 3 CROWN trial, which evaluated LORBRENA (lorlatinib, available in Europe under the brand name LORVIQUA) versus XALKORI (crizotinib) in people with previously untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

April 10, 2022 Off

Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting

By Dino Mustafić

Affimed N.V. (Nasdaq: AFMD) has provided a data update from the ongoing study of the company’s lead innate cell engager (ICE) AFM13 precomplexed with cord blood-derived natural killer (cbNK) cells.